Evolent Health, Inc. (EVH)
NYSE: EVH · IEX Real-Time Price · USD
27.65
-0.67 (-2.37%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Evolent Health Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Evolent Health stock have an average target of 42.33, with a low estimate of 34 and a high estimate of 52. The average target predicts an increase of 53.09% from the current stock price of 27.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 3 | 4 | 4 | 3 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $40 | Strong Buy | Initiates | $40 | +44.67% | Apr 22, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +59.13% | Mar 28, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $53 → $52 | Buy | Maintains | $53 → $52 | +88.07% | Mar 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $45 | Buy | Initiates | $45 | +62.75% | Mar 1, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $37 → $38 | Buy | Maintains | $37 → $38 | +37.43% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
2.49B
from 1.96B
Increased by 26.94%
Revenue Next Year
2.89B
from 2.49B
Increased by 15.80%
EPS This Year
1.17
from -1.28
EPS Next Year
1.65
from 1.17
Increased by 40.61%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.7B | 3.2B | 3.7B | 4.0B | 3.8B |
| Avg | 2.5B | 2.9B | 3.3B | 3.6B | 3.6B |
| Low | 2.4B | 2.7B | 2.9B | 3.2B | 3.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.9% | 28.4% | 28.2% | 21.4% | 5.6% |
| Avg | 26.9% | 15.8% | 14.5% | 7.9% | 1.5% |
| Low | 20.9% | 6.3% | -0.1% | -3.9% | -1.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 1.72 | 2.52 | 2.36 | 2.54 |
| Avg | 1.17 | 1.65 | 1.88 | 2.44 |
| Low | 0.61 | 1.18 | 1.38 | 2.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 115.4% | 43.6% | 35.4% |
| Avg | - | 40.6% | 14.1% | 30.2% |
| Low | - | 0.5% | -16.0% | 26.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.